The state of your journal

Acta Ophthalmologica

Volumn 86, Issue 3, 2008, Pages 243-244

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR;

BLUE LIGHT; EDITORIAL; HUMAN; INFORMATION DISSEMINATION; INTERPERSONAL COMMUNICATION; OPHTHALMOLOGY; PRIORITY JOURNAL; PUBLICATION; RADIATION HAZARD; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULOPATHY; RETINA TEAR; SCIENTIFIC LITERATURE;

EID: 44649108979     PISSN: 1755375X     EISSN: 16000420     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2008.01284.x     Document Type: Editorial

References (5)

1. Algvere PV, Marshall J & Seregard S (2006): Age-related maculopathy and the impact of blue light hazard. Acta Ophthalmol Scand 84: 4-15.
2. la Cour M (2007): IntravItreal VEGF-inhibitors: is Avastin® a generic substitute for Lucentis ®? Acta Ophthalmol Scand 85: 2-4.
3. Gelisken F, Ziemssen F, Voelker M & Bartz-Schmidt KU (2006): Retinal pigment epithelial tear following intravitreal bevacizumab injection for neovascular age-related macular degeneration. Acta Ophthalmol Scand 84: 833-834.
4. Schmidt-Erfurth UM, Richard G, Augustin A, Aylward WG, Bandello F, Corcòstegui B, Cunha-Vaz J & Schlingemann RO (2007): Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand 85: 486-494.
5. Virgili G, Do DV, Bressler NM & Menchini U (2007): New therapies for neovascular age-related macular degeneration: Critical appraisal of the current evidence. Acta Ophthalmol Scand 85: 6-20.